Artificial intelligence (AI) has the potential to revolutionize healthcare, but thoughtful regulations are needed in order ...
Stanford physician-scientist joins the Academy’s Class of 2026, bringing expertise in cardiovascular medicine, stem-cell ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today ...
Remission and Endoscopic Response with RINVOQ for Advanced and Difficult-to-Treat Crohn's Disease ...
Second of Four Planned Modules Moves Rolling FDA Review Forward Advances Toward Targeted Completion of the Final Clinical ...
Phoenix Children’s has appointed Wanda Shoer, MBA, as Senior Vice President and Chief People Officer, effective Nov. 2. In ...
The centerpiece of Bristol Myers Squibb’s 2024 RayzeBio buy has read out, hitting the primary endpoint in a late-stage tumor ...
Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the ...
Dose escalation is ongoing in the OSPREY study, with the first two dose cohorts now complete and the third cohort expected to ...
Phase 1b study in atopic dermatitis demonstrated a statistically significant mean reduction of 2.1 years in measured skin ...
Compared with standard povidone-iodine (PVP-I), I2Pure's formulations exhibited minimal residual staining and were readily ...
Additional presentations highlight the design of an ongoing Phase 3 study evaluating tenapanor in chronic idiopathic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results